Wird geladen...

Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis

Ruxolitinib is a recommended second-line treatment for the prevention of thrombosis in patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however, evidence regarding its efficacy in terms of thrombosis reduction is uncertain. We searched Medline, Embase, and archives...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Masciulli, Arianna, Ferrari, Alberto, Carobbio, Alessandra, Ghirardi, Arianna, Barbui, Tiziano
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2020
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988397/
https://ncbi.nlm.nih.gov/pubmed/31985808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001158
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!